A short primer on a preclinical research article testing a small‑molecule adiponectin receptor agonist as a potential way to stimulate muscle growth and function in rodent models, useful for readers curious about emerging pharmacological strategies against muscle atrophy.
Key Takeaways
- Therapies that inhibit myostatin or upregulate follistatin signaling are under development
- But most of the research community is focused on pharmacology
- Skeletal muscle atrophy is a hallmark of ageing and chronic diseases, yet effective pharmacotherapies remain unavailable